Short answer
MERIT MEDICAL SYSTEMS INC (MMSI) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.1#2 (Exhibit EX-99.1). Press release announces Merit Medical’s operating and financial results for quarter ended June 30, 2026.
MERIT MEDICAL SYSTEMS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release announces Merit Medical’s operating and financial results for quarter ended June 30, 2026
- Exhibit 99.1 contains the detailed earnings release for investor review
Item 7.01 · Regulation FD Disclosure
- Q2 2026 results conference call scheduled for July 30, covering the quarter ended June 30, 2026
- Earnings press release and presentation furnished as Exhibits 99.1 and 99.2
- Non-GAAP results included alongside GAAP metrics, with historical reconciliations
- No GAAP guidance beyond revenue, limiting comparability with adjusted outlook measures
- Unpredictable acquisition, amortization, severance, litigation and regulatory costs may materially affect GAAP results
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $418.8M, up 10%; organic constant-currency growth 9%, signaling broad-based demand acceleration
- Non-GAAP operating margin 22.6% vs 21.2%; GAAP EPS $0.65, up 20%, demonstrating strong operating leverage
- Therapeutic revenue up 15%, led by Endoscopy up 29% and Cardiac Therapies up 24%; Procedural Solutions declined 12%
- 2026 guidance raised to revenue $1.631–$1.643B and non-GAAP EPS $4.25–$4.35
- Year-to-date operating cash flow $110.0M, down 11%; debt $747.5M versus cash $448.7M, limiting balance-sheet flexibility despite approximately $697M borrowing capacity
Item EX-99.1#2 · Exhibit EX-99.1
- Q2 revenue $418.8M, up 9.5%, with domestic growth 11.0% and international growth 7.3%
- GAAP operating margin 14.4% versus 12.3%, while EPS rose 20.3% to $0.65
- Organic constant-currency revenue increased 9.0%, indicating growth beyond acquired businesses and currency effects
- 2026 guidance raised: revenue $1.631-$1.643B and non-GAAP EPS $4.25-$4.35
- Operating cash flow fell to $69.3M from $83.3M, warranting attention despite stronger earnings growth
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MERIT MEDICAL SYSTEMS INC 8-K filings
Get the next MMSI 8-K as it lands
Follow MMSI for push alerts, or ask the research agent what this filing means.